Who Generates Higher Gross Profit? Evotec SE or MiMedx Group, Inc.

Biotech Giants: Evotec vs. MiMedx in Gross Profit Battle

__timestampEvotec SEMiMedx Group, Inc.
Wednesday, January 1, 201429378000105558000
Thursday, January 1, 201537987000167094000
Friday, January 1, 201658554000212608000
Sunday, January 1, 201782568000285920000
Monday, January 1, 2018112016000322725000
Tuesday, January 1, 2019132891000256174000
Wednesday, January 1, 2020125743000208904000
Friday, January 1, 2021151543000215332000
Saturday, January 1, 2022174065000219525000
Sunday, January 1, 2023175051000266843000
Loading chart...

Cracking the code

A Tale of Two Companies: Evotec SE vs. MiMedx Group, Inc.

In the competitive landscape of the biotechnology sector, Evotec SE and MiMedx Group, Inc. have been vying for dominance in gross profit generation over the past decade. From 2014 to 2023, MiMedx Group, Inc. consistently outperformed Evotec SE, boasting a gross profit that was, on average, more than double that of its competitor. Notably, in 2018, MiMedx reached a peak, generating approximately 3.2 times the gross profit of Evotec. However, Evotec has shown remarkable growth, with its gross profit increasing by nearly 500% from 2014 to 2023. This upward trend suggests a promising trajectory for Evotec, potentially narrowing the gap in the coming years. As the biotech industry continues to evolve, these two companies exemplify the dynamic shifts and competitive spirit that drive innovation and growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025